459 related articles for article (PubMed ID: 26876596)
1. DNMT3A(R882H) mutant and Tet2 inactivation cooperate in the deregulation of DNA methylation control to induce lymphoid malignancies in mice.
Scourzic L; Couronné L; Pedersen MT; Della Valle V; Diop M; Mylonas E; Calvo J; Mouly E; Lopez CK; Martin N; Fontenay M; Bender A; Guibert S; Dubreuil P; Dessen P; Droin N; Pflumio F; Weber M; Gaulard P; Helin K; Mercher T; Bernard OA
Leukemia; 2016 Jun; 30(6):1388-98. PubMed ID: 26876596
[TBL] [Abstract][Full Text] [Related]
2. Mutations in TET2 and DNMT3A genes are associated with changes in global and gene-specific methylation in acute myeloid leukemia.
Ponciano-Gómez A; Martínez-Tovar A; Vela-Ojeda J; Olarte-Carrillo I; Centeno-Cruz F; Garrido E
Tumour Biol; 2017 Oct; 39(10):1010428317732181. PubMed ID: 28992762
[TBL] [Abstract][Full Text] [Related]
3. DNMT3A
Zheng J; Wang Z; Pan X; Zhang Z; Li H; Deng X; Liu P; Zhang Q; Na F; Chen C; Niu T; Liu Y
Oncogene; 2023 Jun; 42(23):1940-1950. PubMed ID: 37127775
[TBL] [Abstract][Full Text] [Related]
4. Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia.
Sasaki K; Kanagal-Shamanna R; Montalban-Bravo G; Assi R; Jabbour E; Ravandi F; Kadia T; Pierce S; Takahashi K; Nogueras Gonzalez G; Patel K; Soltysiak KA; Cortes J; Kantarjian HM; Garcia-Manero G
Cancer; 2020 Feb; 126(4):765-774. PubMed ID: 31742675
[TBL] [Abstract][Full Text] [Related]
5. Effect of
Tabatabaei T; Rezvany MR; Ghasemi B; Vafaei F; Zadeh MK; Zaker F; Salmaninejad A
Biomed Res Int; 2024; 2024():9625043. PubMed ID: 38807916
[TBL] [Abstract][Full Text] [Related]
6. TET2 and DNMT3A mutations and exceptional response to 4'-thio-2'-deoxycytidine in human solid tumor models.
Yang SX; Hollingshead M; Rubinstein L; Nguyen D; Larenjeira ABA; Kinders RJ; Difilippantonio M; Doroshow JH
J Hematol Oncol; 2021 May; 14(1):83. PubMed ID: 34039392
[TBL] [Abstract][Full Text] [Related]
7. DNMT3A R882H mutation promotes acute leukemic cell survival by regulating glycolysis through the NRF2/NQO1 axis.
Chu X; Zhong L; Dan W; Wang X; Zhang Z; Liu Z; Lu Y; Shao X; Zhou Z; Chen S; Liu B
Cell Signal; 2023 May; 105():110626. PubMed ID: 36758683
[TBL] [Abstract][Full Text] [Related]
8. Structural basis for impairment of DNA methylation by the DNMT3A R882H mutation.
Anteneh H; Fang J; Song J
Nat Commun; 2020 May; 11(1):2294. PubMed ID: 32385248
[TBL] [Abstract][Full Text] [Related]
9. DNMT3A R882H mutation drives daunorubicin resistance in acute myeloid leukemia via regulating NRF2/NQO1 pathway.
Chu X; Zhong L; Dan W; Wang X; Zhang Z; Liu Z; Lu Y; Shao X; Zhou Z; Chen S; Liu B
Cell Commun Signal; 2022 Oct; 20(1):168. PubMed ID: 36303144
[TBL] [Abstract][Full Text] [Related]
10. Angioimmunoblastic T cell lymphoma: novel molecular insights by mutation profiling.
Wang M; Zhang S; Chuang SS; Ashton-Key M; Ochoa E; Bolli N; Vassiliou G; Gao Z; Du MQ
Oncotarget; 2017 Mar; 8(11):17763-17770. PubMed ID: 28148900
[TBL] [Abstract][Full Text] [Related]
11. The R882H DNMT3A hot spot mutation stabilizes the formation of large DNMT3A oligomers with low DNA methyltransferase activity.
Nguyen TV; Yao S; Wang Y; Rolfe A; Selvaraj A; Darman R; Ke J; Warmuth M; Smith PG; Larsen NA; Yu L; Zhu P; Fekkes P; Vaillancourt FH; Bolduc DM
J Biol Chem; 2019 Nov; 294(45):16966-16977. PubMed ID: 31582562
[TBL] [Abstract][Full Text] [Related]
12. CRISPR-Mediated Gene Editing to Assess the Roles of Tet2 and Dnmt3a in Clonal Hematopoiesis and Cardiovascular Disease.
Sano S; Oshima K; Wang Y; Katanasaka Y; Sano M; Walsh K
Circ Res; 2018 Jul; 123(3):335-341. PubMed ID: 29728415
[TBL] [Abstract][Full Text] [Related]
13. Mutations of R882 change flanking sequence preferences of the DNA methyltransferase DNMT3A and cellular methylation patterns.
Emperle M; Adam S; Kunert S; Dukatz M; Baude A; Plass C; Rathert P; Bashtrykov P; Jeltsch A
Nucleic Acids Res; 2019 Dec; 47(21):11355-11367. PubMed ID: 31620784
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic Perturbations by Arg882-Mutated DNMT3A Potentiate Aberrant Stem Cell Gene-Expression Program and Acute Leukemia Development.
Lu R; Wang P; Parton T; Zhou Y; Chrysovergis K; Rockowitz S; Chen WY; Abdel-Wahab O; Wade PA; Zheng D; Wang GG
Cancer Cell; 2016 Jul; 30(1):92-107. PubMed ID: 27344947
[TBL] [Abstract][Full Text] [Related]
15. DNMT3A mutation promotes leukemia development through NAM-NAD metabolic reprogramming.
Yang X; Wang X; Yang Y; Li Z; Chen Y; Shang S; Wang Y
J Transl Med; 2023 Jul; 21(1):481. PubMed ID: 37464424
[TBL] [Abstract][Full Text] [Related]
16. Somatic RHOA mutation in angioimmunoblastic T cell lymphoma.
Sakata-Yanagimoto M; Enami T; Yoshida K; Shiraishi Y; Ishii R; Miyake Y; Muto H; Tsuyama N; Sato-Otsubo A; Okuno Y; Sakata S; Kamada Y; Nakamoto-Matsubara R; Tran NB; Izutsu K; Sato Y; Ohta Y; Furuta J; Shimizu S; Komeno T; Sato Y; Ito T; Noguchi M; Noguchi E; Sanada M; Chiba K; Tanaka H; Suzukawa K; Nanmoku T; Hasegawa Y; Nureki O; Miyano S; Nakamura N; Takeuchi K; Ogawa S; Chiba S
Nat Genet; 2014 Feb; 46(2):171-5. PubMed ID: 24413737
[TBL] [Abstract][Full Text] [Related]
17. Measurable residual disease of canonical versus non-canonical DNMT3A, TET2, or ASXL1 mutations in AML at stem cell transplantation.
Jentzsch M; Grimm J; Bill M; Küpper J; Backhaus D; Brauer D; Schulz J; Franke GN; Vucinic V; Niederwieser D; Platzbecker U; Schwind S
Bone Marrow Transplant; 2021 Oct; 56(10):2610-2612. PubMed ID: 34267355
[No Abstract] [Full Text] [Related]
18. Cooperating gene mutations in childhood acute myeloid leukemia with special reference on mutations of ASXL1, TET2, IDH1, IDH2, and DNMT3A.
Liang DC; Liu HC; Yang CP; Jaing TH; Hung IJ; Yeh TC; Chen SH; Hou JY; Huang YJ; Shih YS; Huang YH; Lin TH; Shih LY
Blood; 2013 Apr; 121(15):2988-95. PubMed ID: 23365461
[TBL] [Abstract][Full Text] [Related]
19. Clonal haematopoiesis in chronic ischaemic heart failure: prognostic role of clone size for DNMT3A- and TET2-driver gene mutations.
Assmus B; Cremer S; Kirschbaum K; Culmann D; Kiefer K; Dorsheimer L; Rasper T; Abou-El-Ardat K; Herrmann E; Berkowitsch A; Hoffmann J; Seeger F; Mas-Peiro S; Rieger MA; Dimmeler S; Zeiher AM
Eur Heart J; 2021 Jan; 42(3):257-265. PubMed ID: 33241418
[TBL] [Abstract][Full Text] [Related]
20. Impact of constitutional TET2 haploinsufficiency on molecular and clinical phenotype in humans.
Kaasinen E; Kuismin O; Rajamäki K; Ristolainen H; Aavikko M; Kondelin J; Saarinen S; Berta DG; Katainen R; Hirvonen EAM; Karhu A; Taira A; Tanskanen T; Alkodsi A; Taipale M; Morgunova E; Franssila K; Lehtonen R; Mäkinen M; Aittomäki K; Palotie A; Kurki MI; Pietiläinen O; Hilpert M; Saarentaus E; Niinimäki J; Junttila J; Kaikkonen K; Vahteristo P; Skoda RC; Seppänen MRJ; Eklund KK; Taipale J; Kilpivaara O; Aaltonen LA
Nat Commun; 2019 Mar; 10(1):1252. PubMed ID: 30890702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
